Eleven questions on Hantavirus cardiopulmonary syndrome management in the ICU
9 affiliations
- 1Departamento de Medicina Interna, Facultad de Medicina, Universidad de Concepción, Concepción, Chile
- 2Unidad de Cuidados Intensivos, Hospital Guillermo Grant Benavente, Concepción, Chile
- 3Departamento de Enfermedades Infecciosas e Inmunología Pediátricas, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile
- 4SENTINET: Surveillance, Epidemiology, and New Technologies for Infectious Emerging Threats, Santiago, Chile
- 5Departamento de Medicina Intensiva, Facultad de Medicina, Pontificia Universidad Católica de Chile, Avenida Diagonal Paraguay 362, Santiago, Chile
- 6Unisabana Center for Translational Science, School of Medicine, Universidad de La Sabana, Chia, Colombia
- 7Critical Care Department, Clínica Universidad de La Sabana, Chía, Colombia
- 8ISARIC, University of Oxford, Pandemic Sciences Institute, Oxford, UK
- 9The Latin American Intensive Care Research Network (LIVEN)
Abstract
Hantavirus cardiopulmonary syndrome (HCPS) due to Andes virus (ANDV) is a fulminant yet potentially reversible cause of respiratory and circulatory failure requiring timely critical care. This article addresses eleven practical questions on ICU management, drawing on clinical experience and research from the Chilean healthcare system. The recommendations cover early recognition, diagnostic workup, haemodynamic monitoring, cautious fluid and vasoactive support, respiratory management, VA-ECMO referral, daily ICU care, recovery, common pitfalls, and therapies with limited evidence. Because no antiviral or immunomodulatory therapy has consistently improved outcomes, survival relies on early suspicion, physiology-guided supportive care, and rapid escalation to ECMO-capable centres when severe cardiopulmonary failure develops.
Related
- When rare zoonoses travel: Andes virus, hantavirus cardiopulmonary syndrome, and the preparedness gap
- A Case Report of Hantavirus Capillary Leak Syndrome in the Southwestern United States.
- Management of patients with cardiopulmonary comorbidities awaiting liver transplantation
- Cerebral Oxygenation-Guided Indexed-Flow Normothermic Cardiopulmonary Bypass with Vasopressor-Sparing Pressure Management: A Retrospective Descriptive Cohort Study
- From Measurement to Management ― Lipoprotein(a) After Acute Coronary Syndrome ―
BibTeX
@article{pavez2026eleven,
title = {{Eleven questions on Hantavirus cardiopulmonary syndrome management in the ICU}},
author = {Nicolás Pavez and Paula Fernández and Marcela Ferrés and Jaime Retamal and Luis Felipe Reyes and Eduardo Kattan and Alejandro Bruhn},
journal = {Critical Care},
year = {2026},
month = aug,
doi = {10.1186/s13054-026-06233-0},
url = {https://doi.org/10.1186/s13054-026-06233-0},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Eleven questions on Hantavirus cardiopulmonary syndrome management in the ICU
AU - Nicolás Pavez
AU - Paula Fernández
AU - Marcela Ferrés
AU - Jaime Retamal
AU - Luis Felipe Reyes
AU - Eduardo Kattan
AU - Alejandro Bruhn
PY - 2026
DA - 2026/08/09
JO - Critical Care
DO - 10.1186/s13054-026-06233-0
UR - https://doi.org/10.1186/s13054-026-06233-0
AB - Hantavirus cardiopulmonary syndrome (HCPS) due to Andes virus (ANDV) is a fulminant yet potentially reversible cause of respiratory and circulatory failure requiring timely critical care. This article addresses eleven practical questions on ICU management, drawing on clinical experience and research from the Chilean healthcare system. The recommendations cover early recognition, diagnostic workup, haemodynamic monitoring, cautious fluid and vasoactive support, respiratory management, VA-ECMO referral, daily ICU care, recovery, common pitfalls, and therapies with limited evidence. Because no antiviral or immunomodulatory therapy has consistently improved outcomes, survival relies on early suspicion, physiology-guided supportive care, and rapid escalation to ECMO-capable centres when severe cardiopulmonary failure develops.
SN - 1364-8535
SN - 1466-609X
ER -